Company Overview
bioAffinity Technologies, Inc. is a specialized entity within the Healthcare sector, specifically focusing on the Diagnostics & Research industry, where it develops non-invasive diagnostic laboratory tests designed to detect early-stage lung cancer and other pulmonary diseases. This operational focus relies on advanced technologies such as flow cytometry and automated analysis to deliver critical diagnostic information in the United States market. The company currently maintains a market capitalization of $17.99M and employs a workforce of 57 individuals to support its operations across its Diagnostic Research and Development segments. With annual revenue of $6.16M, the company operates as a micro-cap entity, indicating a small market position with limited scale relative to large-cap peers in the healthcare diagnostic space.
Financial Health
The company reported revenue of $6.16M over the trailing twelve months, yet generated a net income of $-14,909,754 and an EBITDA of $-10,067,672, revealing a significant cost structure where operating expenses vastly exceed revenue generation. This substantial gap between positive revenue and negative net income indicates that the company is currently burning cash to fund its research and development activities rather than generating profit from sales. Free cash flow stands at $-4,933,569, which signifies a lack of financial flexibility and a reliance on external capital sources to sustain operations without immediate operational cash generation. The company's margin profile shows a gross margin of 31.4%, suggesting that the core production of its diagnostic tests retains a reasonable portion of revenue after cost of goods sold, but this is negated by an operating margin of -196.9% and a profit margin of -242.0%. These negative margins reflect high overhead costs, likely driven by R&D investments and administrative expenses, which consume the entire revenue base and generate losses on every dollar of sales. In terms of leverage, the company holds $6.45M in cash against $1.16M in debt, resulting in a debt-to-equity ratio of 15.95, which suggests a balance sheet that is technically leveraged in accounting terms due to the equity base being small relative to debt, though the cash position provides a buffer. The current ratio is 2.60, indicating that the company possesses 2.60 dollars of current assets for every dollar of current liabilities, which points to adequate short-term liquidity to meet its immediate obligations. Finally, the Return on Equity is -301.8% and the Return on Assets is -75.6%, metrics that reveal that management is currently destroying shareholder value and utilizing assets inefficiently in terms of profit generation, a common trait for pre-profitability growth-stage biotech firms.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is -6.67, implying that the market is pricing in expectations of future earnings recovery or continued losses that have not yet materialized into a positive multiple. The price-to-book ratio is 2.47, indicating that the market values the company at 2.47 times its book value, which suggests a premium over the net asset value often seen in firms with valuable intangible assets like intellectual property or high growth potential. The price-to-sales ratio is 2.92, and the EV/EBITDA is -1.26, offering alternative valuation perspectives where the market is willing to pay nearly three times revenue for the company despite the negative earnings multiple. The stock has traded between a 52-week low of $0.69 and a 52-week high of $46.53, meaning the current trading price sits significantly below the recent high and near the bottom of its historical volatility range, reflecting high uncertainty. The beta value is 2.44, which means the stock's price volatility is more than twice that of the broader market, indicating high sensitivity to market movements and increased risk for investors.
Growth & Income
Revenue growth year-over-year has declined by 27.8%, while earnings growth is N/A due to the absence of positive earnings in the prior period, implying that the company is in a contractionary phase regarding top-line sales rather than an expansionary growth phase. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means it reinvests all available resources and negative earnings into growth initiatives like research and development rather than distributing income to shareholders. This strategy prioritizes long-term product development and market penetration over immediate income returns, a typical approach for early-stage diagnostics companies aiming to validate their technology. The overall growth and income profile characterizes bioAffinity Technologies as a high-risk, non-income-generating asset with shrinking revenue that relies entirely on capital infusion to potentially achieve profitability in the future.